Ticker: TSX – TOS
Shares Outstanding: 82,617,989
QUÉBEC CITY, July 9, 2015 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has received Notice of Acceptance from the US Patent Office for the first of several patent applications covering critical aspects of TSO3's technology. This technology is embedded in the TSO3 STERIZONE® Sterilization System. Furthermore, recently five additional patents have been granted in Japan while another one, representing a fifth patent in Europe, has been granted.
"We are extremely pleased to see the granting of these patents" stated R.M. (Ric) Rumble, President and CEO. "These patents cover our sterilization method and the use of our Dynamic Sterilant Delivery System™ using the two sterilants of hydrogen peroxide and ozone. This protection provides the Company the right to exclude others from utilizing TSO3 technology. The Company maintains a number of active applications on additional innovative aspects of its superior sterilization technology and these applications are still pending. Investing in the protection of our technology is core to creating value in our organization and for our shareholders." concluded Mr. Rumble.
About the STERIZONE® VP4 low temperature sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section: http://www.tso3.com/en/products/sterizone-vp4/
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: R.M. (Ric) Rumble, President and CEO, 418 651-0003, Email: firstname.lastname@example.org